As further knowledge about the mechanisms that favour the pro-tumourigenic actions of TGF-β is requested for rationalising TGF-β directed drugs to treat HCC in human, we suggest expression of CAV1 as a potential molecular marker for better stratification of patients prone for such therapy. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.